FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
As an independent predictor of metastatic disease (p<0.001), the percentage of patients with metastatic disease at diagnosis who had PSA > 20 increased from 54% in 2004 versus the present 72% in 2014 – a 1.3 fold increase in proportion. In the lowest risk group (PSA < 4), the proportion resenting with metastatic disease also experienced a proportional increase: from 0.92% in 2004 to 2.65% in 2014 – a 2.88 fold increase.
While PSA is indeed a rough metric for prostate cancer progression, there is little change that these results were from happenstance. The higher disease burden at diagnosis (and treatment) correlates closely with the 2008 and 2012 grade D recommendations. Although further studies are required to establish a causative relationship, this reverse stage migration in the contemporary PSA screening era raises concern for biochemical recurrence, metastatic disease presentation, and prostate cancer specific mortality.
Authors: Jared P. Schober*, Kristian D. Stensland, Karim Hamawy, Alireza Moinzadeh, David Canes
Presented by: Jared Schober, MD, Lahey Hospital & Medical Center
Written By: Linda Huynh (BS), an assistant research specialist from the University of California, Irvine, on behalf of UroToday.com
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA